Compare Cincinnati Financial Corporation (CINF) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs GSK plc — how do they compare? Cincinnati Financial Corporation trades at $182.62 (market cap $27.85B), while GSK plc trades at $51.21 (market cap $101.55B). The key difference: GSK plc is far larger — about 3.6× Cincinnati Financial Corporation's market cap, and GSK plc pays the higher dividend (3.5%). Which is the better fit depends on your goals.
| CINF | GSK | |
|---|---|---|
Market Cap | $27.85B | $101.55B |
Sector | Financials | Health |
52-Week High | $192.03 | $61.18 |
52-Week Low | $145.80 | $36.20 |
Enterprise Value | $27.52B | $122.16B |
Dividend Yield | 2.09% | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $182.67, up 1.89% with strong technical momentum near recent highs. The stock shows solid fundamentals with a P/E of 10.44, ROE of 18.73%, and consistent earnings beats in recent quarters. Recent news highlights the company's 65-year dividend streak and upcoming Q2 2026 earnings release on July 27, 2026. Operating cash flow improved to $3.11B in 2025, supporting financial stability.
CINF presents a balanced investment case with attractive valuation metrics and strong profitability, though catastrophe losses and claims costs remain key risks. Analyst consensus suggests moderate upside to the $188.67 price target. The stock's technical positioning near resistance at $184 requires monitoring of earnings performance for continued momentum.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
